36 results
Page 2 of 2
8-K
EX-99.1
n17ymhichrse2xvoq7w
29 Nov 22
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
4:30pm
424B5
i2fn9v th0s
9 Nov 22
Prospectus supplement for primary offering
4:29pm
8-K
EX-99.1
ms54qs
8 Nov 22
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:19pm
10-Q
pbpv77xl
8 Nov 22
Quarterly report
4:09pm
424B5
z94r4oh5
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.2
capy3r5uwics73nbj72
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
8-K
EX-99.1
45d6ztnngrh q5xi107
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
bhxkc13h
13 Oct 22
Prospectus supplement for primary offering
4:56pm
424B3
xetdnvigr98
2 Sep 22
Prospectus supplement
4:06pm
S-4/A
y3hl h3nx1
19 Aug 22
Registration of securities issued in business combination transactions (amended)
4:47pm
425
37bhtw kb
15 Jul 22
Business combination disclosure
5:26pm
425
z6d ql6wjq
15 Jul 22
Business combination disclosure
5:23pm
425
t2qdiecuy48s
15 Jul 22
Business combination disclosure
5:21pm
425
ykooa3k57p
15 Jul 22
Business combination disclosure
5:19pm
425
xmjhnqx6om6i9fb
15 Jul 22
Business combination disclosure
5:12pm
S-4
ikp wy206
15 Jul 22
Registration of securities issued in business combination transactions
4:04pm